What To Know About The Bundibugyo Virus

June 5, 2026

An outbreak in Congo that has killed over 200 people is caused by the Bundibugyo virus, a rare strain that causes Ebola disease but lacks specific approved treatments or vaccines. Unlike more common Ebola strains, Bundibugyo has only caused two previous outbreaks, all in the Congo River basin region, and appears to have a mortality rate around 30% or higher. Health officials have identified several potential vaccines and therapies for testing, including candidates from Moderna, the Serum Institute of India, and antibody treatments from pharmaceutical companies, but these require months of development before clinical trials can begin.

Who is affected

More than 200 people killed in Congo
Healthcare workers and nurses (described as among the first to be infected and die)
Family members caring for sick patients
People in the Congo River basin region
Aid workers and outbreak responders
Close contacts of Ebola victims

What action is being taken

Health workers are finding and isolating cases
Responders are tracing contacts of infected individuals
Health workers are educating people about virus avoidance
Medical teams are providing supportive medical care to patients (IV or oral fluids)
Healthcare workers are using proper protective equipment
The International AIDS Vaccine Initiative is developing a Bundibugyo-specific vaccine
India's Serum Institute is making vaccine doses
Moderna is building off earlier research and conducting early safety tests

Why it matters

This outbreak is significant because the Bundibugyo virus lacks approved vaccines and treatments, forcing responders to rely solely on basic public health measures rather than advanced medical interventions. Healthcare workers face especially high risk due to transmission through bodily fluids during patient care, making them among the first casualties. The 30%-plus mortality rate makes this a deadly disease, though potentially less lethal than other Ebola strains. The outbreak demonstrates ongoing vulnerability to rare pathogens for which the medical community has limited preparedness, and highlights the challenges of responding to diseases with little prior research and no available pharmaceutical countermeasures.

What's next

Vaccine candidates will require months of development before clinical trials can begin
The Bundibugyo-specific vaccine would likely need at least seven months before clinical trial testing
Serum Institute doses could become available within two to three months for a clinical trial (though more animal testing is needed)
WHO's independent experts recommended prioritizing three therapies (Mapp's MBP134, Regeneron's maftivimab, and Gilead's remdesivir) for clinical trials
Gilead's obeldesivir should be evaluated to see if it prevents close contacts from developing Ebola disease

Read full article from source: The San Diego Voice & Viewpoint